國立虎尾科技大學 |

Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy = A Handbook for Diagnosis and Management /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy/ edited by Maria E. Suarez-Almazor, Leonard H. Calabrese.
Reminder of title:	A Handbook for Diagnosis and Management /
other author:	Suarez-Almazor, Maria E.
Description:	XIV, 363 p. 19 illus., 16 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Rheumatology. -
Online resource:	https://doi.org/10.1007/978-3-030-56824-5
ISBN:	9783030568245

Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy = A Handbook for Diagnosis and Management /
Rheumatic Diseases and Syndromes Induced by Cancer ImmunotherapyA Handbook for Diagnosis and Management /[electronic resource] :edited by Maria E. Suarez-Almazor, Leonard H. Calabrese. - 1st ed. 2021. - XIV, 363 p. 19 illus., 16 illus. in color.online resource.

PART 1 - INTRODUCTION -- 1. Cancer Immunology and the evolution of immunotherapy -- 2. Cancer immunotherapy: overview -- 3. Pathogenesis of immune-related adverse events -- PART 2 – IMMUNE-RELATED ADVERSE EVENTS WITH IMMUNE-CHECKPOINT INHIBITORS -- 4. Arthritis -- 5. Polymyalgia rheumatica -- 6. Myositis -- 7. Sicca syndromes -- 8. Sarcoidosis -- 9. Miscellaneous rheumatic syndromes -- 10. Non-rheumatic immune-related adverse events -- 11. Immune-related adverse events with other cancer immunotherapies -- PART 3 – CANCER IMMUNOTHERAPY IN PATIENTS WITH PRE-EXISTING RHEUMATIC DISEASES -- 12. Inflammatory arthritis -- 13. Other rheumatic autoimmune diseases -- 14. Choosing the right therapy -- 15. Risk-benefit considerations -- 16. Patient education and shared-decision making.

With the increasing use of immune checkpoint inhibitors (ICI) across various cancers, the trends for indication at earlier stages, and the use of combination immunotherapy, the frequency of ICI-induced immune-related adverse events (irAE) is expected to grow substantially. Management of these irAE is challenging as it requires not only consideration of the toxicity but also risk-benefit ratios with respect to the primary cancer. Several rheumatic irAE have been reported with ICI therapy including arthritis, myositis, polymyalgia-like syndromes, sicca/Sjogren-like manifestations, and several other less common systemic autoimmune features commonly associated with connective tissue disease. This handbook provides clinicians with a comprehensive overview of the management of rheumatic irAE that develop from cancer immunotherapy. It focuses on the irAE seen with ICI, the most frequently used agents in treating cancer. It provides an overview of cancer immunology, immunotoxicity, and immunotherapies such as ICI, cytokine-based therapy, and CART. It examines the epidemiology, clinical manifestations, diagnosis, differential diagnosis, and treatment of a variety of rheumatic immune-related adverse events arising from these therapies. Chapters also cover cancer immunotherapy in patients with preexisting rheumatic diseases such as inflammatory arthritis and other connective tissue disorders. The book helps clinicians to distinguish the current types of cancer immunotherapy and general toxicity patterns, recognize and diagnose rheumatic clinical syndromes, understand the pathogenesis of irAE, and consider risk–benefit ratios when managing patients with rheumatic irAE. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy is an essential resource for physicians and related professionals, residents, fellows, graduate students and nurses alike in rheumatology, clinical immunology, oncology, and internal medicine.

ISBN: 9783030568245

Standard No.: 10.1007/978-3-030-56824-5doiSubjects--Topical Terms:

668542
Rheumatology.

LC Class. No.: RC927-927.5

Dewey Class. No.: 616.723

Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy = A Handbook for Diagnosis and Management /
LDR:04105nam a22003855i 4500 001 1053390
003 DE-He213
005 20210818190431.0
007 cr nn 008mamaa
008 220103s2021 sz | s |||| 0|eng d
020 $a 9783030568245 $9 978-3-030-56824-5
024 7 $a 10.1007/978-3-030-56824-5 $2 doi
035 $a 978-3-030-56824-5
050 4 $a RC927-927.5
072 7 $a MJM $2 bicssc
072 7 $a MED083000 $2 bisacsh
072 7 $a MJM $2 thema
082 0 4 $a 616.723 $2 23
245 1 0 $a Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy $h [electronic resource] : $b A Handbook for Diagnosis and Management / $c edited by Maria E. Suarez-Almazor, Leonard H. Calabrese.
250 $a 1st ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a XIV, 363 p. 19 illus., 16 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a PART 1 - INTRODUCTION -- 1. Cancer Immunology and the evolution of immunotherapy -- 2. Cancer immunotherapy: overview -- 3. Pathogenesis of immune-related adverse events -- PART 2 – IMMUNE-RELATED ADVERSE EVENTS WITH IMMUNE-CHECKPOINT INHIBITORS -- 4. Arthritis -- 5. Polymyalgia rheumatica -- 6. Myositis -- 7. Sicca syndromes -- 8. Sarcoidosis -- 9. Miscellaneous rheumatic syndromes -- 10. Non-rheumatic immune-related adverse events -- 11. Immune-related adverse events with other cancer immunotherapies -- PART 3 – CANCER IMMUNOTHERAPY IN PATIENTS WITH PRE-EXISTING RHEUMATIC DISEASES -- 12. Inflammatory arthritis -- 13. Other rheumatic autoimmune diseases -- 14. Choosing the right therapy -- 15. Risk-benefit considerations -- 16. Patient education and shared-decision making.
520 $a With the increasing use of immune checkpoint inhibitors (ICI) across various cancers, the trends for indication at earlier stages, and the use of combination immunotherapy, the frequency of ICI-induced immune-related adverse events (irAE) is expected to grow substantially. Management of these irAE is challenging as it requires not only consideration of the toxicity but also risk-benefit ratios with respect to the primary cancer. Several rheumatic irAE have been reported with ICI therapy including arthritis, myositis, polymyalgia-like syndromes, sicca/Sjogren-like manifestations, and several other less common systemic autoimmune features commonly associated with connective tissue disease. This handbook provides clinicians with a comprehensive overview of the management of rheumatic irAE that develop from cancer immunotherapy. It focuses on the irAE seen with ICI, the most frequently used agents in treating cancer. It provides an overview of cancer immunology, immunotoxicity, and immunotherapies such as ICI, cytokine-based therapy, and CART. It examines the epidemiology, clinical manifestations, diagnosis, differential diagnosis, and treatment of a variety of rheumatic immune-related adverse events arising from these therapies. Chapters also cover cancer immunotherapy in patients with preexisting rheumatic diseases such as inflammatory arthritis and other connective tissue disorders. The book helps clinicians to distinguish the current types of cancer immunotherapy and general toxicity patterns, recognize and diagnose rheumatic clinical syndromes, understand the pathogenesis of irAE, and consider risk–benefit ratios when managing patients with rheumatic irAE. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy is an essential resource for physicians and related professionals, residents, fellows, graduate students and nurses alike in rheumatology, clinical immunology, oncology, and internal medicine.
650 0 $a Rheumatology. $3 668542
650 0 $a Oncology . $3 1253469
650 0 $a Immunology. $3 592892
650 2 4 $a Oncology. $3 593951
700 1 $a Suarez-Almazor, Maria E. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1358246
700 1 $a Calabrese, Leonard H. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1358247
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030568238
776 0 8 $i Printed edition: $z 9783030568252
856 4 0 $u https://doi.org/10.1007/978-3-030-56824-5
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)